Coronavirus vaccine: AstraZeneca says smaller dosing regime reaches 90% efficacy

Yohay Elam FXStreet

AstraZeneca and the University of Oxford say their COVID-19 vaccine has an average efficacy of 70.4% after recording 131 coronavirus cases within its trial. One dosing regime regiments has shown a higher level of 90% according to the interim results.

The more efficient dosing regime uses half a dose in the first inoculation rather than a full one. That means that more people could be vaccinated using the same amount of material. The 90% efficient regiment is of 1.5 doses rather than two.

From the statement:

One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart...

Excitingly, we’ve found that one of our dosing regimens may be around 90% effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply

AstraZeneca's immunization can be stored at normal cooling temperatures. The firm is set to imminently prepare for emergency regulatory submission. Moderna announced an efficacy of 94.5% and the Pfizer/BioNTech project 95%.

Matt Hancock, the UK's health minister, said that the vaccine is easier to administer and that Britain has 100 million doses in the pipeline. The EU also has a substantial amount of doses for its member states.

Pound/dollar has been standing out in positively responding to immunization news. The currency pair is trading at the highest levels in two months, above 1.33. EUR/USD is also on the rise, changing hands closer to 1.19.

More When the market shivers, the Fed delivers? Where next for markets

Author

Yohay Elam

FXStreet

Yohay is in Forex since 2008 when he founded Forex Crunch, a blog crafted in his free time that turned into a fully-fledged currency website later sold to Finixio.

AUD/USD sits at three-week highs above 0.7000 on hawkish RBA-speak

AUD/USD holds a positive bias for the fourth straight day, trading above 0.7000 in the Asian session on Wednesday and at three-week highs. RBA Deputy Governor Andrew Hauser's hawkish remarks and inflation concerns underpin the pair. However, the upside appears capped as the US Dollar attracts some buyers amid looming US-Iran uncertainty.

USD/JPY remains confined in a familiar range below 158.50

USD/JPY sees some dip-buying in the Asian session on Wednesday, though it remains confined within a multi-week range near 158.50 as the uncertainty over the timing of the next BoJ rate hike keeps Japanese Yen bulls on the defensive. Meanwhile, hawkish Fed expectations, bolstered by inflation risks stemming from volatile oil prices, underpin the US Dollar. However, looming intervention fears could limit JPY losses and cap the currency pair.

Gold appears slightly bid above $4,100

Gold prices manage to reverse three consecutive daily declines, trading just above the $4,100 per troy ounce on Wednesday. The yellow metal’s recovery comes amid a humble advance in the US Dollar, mixed US Treasury yields across the board and a widespread cautious tone from the US-Iran front.

Bitcoin eyes a break above $85,000 as institutional demand returns

Bitcoin edges higher above $83,000, extending its rebound from the 50-day EMA near $80,786. US-listed BTC spot ETFs recorded over $23 million in net inflows on Tuesday, following Monday's $526 million, signaling a return of institutional demand.

What November 3 means for the Fed's rate path and the US Dollar

The USD faces a decisive period ahead of the November 3 midterm elections. While markets anticipate another interest rate increase from the Fed in December, the battle for control of Congress could reshape fiscal policy expectations and, indirectly, the path of US monetary policy in 2027.

The US Dollar fell. Gold didn't rally. That tells you everything

Gold (XAU/USD) is struggling to capitalize on a weaker US Dollar (USD), after repeatedly failing to establish itself above the $4,200 level. The precious metal remains confined to a relatively narrow trading range despite a combination of developments that would normally support higher prices.